193 related articles for article (PubMed ID: 7474190)
1. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing.
Jacobsen SJ; Katusic SK; Bergstralh EJ; Oesterling JE; Ohrt D; Klee GG; Chute CG; Lieber MM
JAMA; 1995 Nov; 274(18):1445-9. PubMed ID: 7474190
[TBL] [Abstract][Full Text] [Related]
2. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota.
Roberts RO; Bergstralh EJ; Katusic SK; Lieber MM; Jacobsen SJ
J Urol; 1999 Feb; 161(2):529-33. PubMed ID: 9915441
[TBL] [Abstract][Full Text] [Related]
3. Predictive properties of serum-prostate-specific antigen testing in a community-based setting.
Jacobsen SJ; Bergstralh EJ; Guess HA; Katusic SK; Klee GG; Oesterling JE; Lieber MM
Arch Intern Med; 1996 Nov; 156(21):2462-8. PubMed ID: 8944739
[TBL] [Abstract][Full Text] [Related]
4. The role of increasing detection in the rising incidence of prostate cancer.
Potosky AL; Miller BA; Albertsen PC; Kramer BS
JAMA; 1995 Feb; 273(7):548-52. PubMed ID: 7530782
[TBL] [Abstract][Full Text] [Related]
5. Decline in the overall incidence of regional-distant prostate cancer in Olmsted County, MN, 1980-2000.
Mullan RJ; Jacobsen SJ; Bergstralh EJ; Slezak JM; Tindall DJ; Lieber MM; Roberts RO
BJU Int; 2005 May; 95(7):951-5. PubMed ID: 15839911
[TBL] [Abstract][Full Text] [Related]
6. Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era.
Tonita JM; Skarsgard D; Muhajarine N
Cancer Causes Control; 2009 Mar; 20(2):201-9. PubMed ID: 18825504
[TBL] [Abstract][Full Text] [Related]
7. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
Roobol MJ; Roobol DW; Schröder FH
Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
[TBL] [Abstract][Full Text] [Related]
8. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997.
Sarma AV; Jacobson DJ; McGree ME; Roberts RO; Lieber MM; Jacobsen SJ
J Urol; 2005 Jun; 173(6):2048-53. PubMed ID: 15879823
[TBL] [Abstract][Full Text] [Related]
9. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
Ellis WJ; Etzioni R; Vessella RL; Hu C; Goodman GE
J Urol; 2001 Jul; 166(1):93-8; discussion 98-9. PubMed ID: 11435831
[TBL] [Abstract][Full Text] [Related]
10. Population-based analysis of prostate-specific antigen (PSA) screening in younger men (<55 years) in Australia.
Ranasinghe WK; Kim SP; Lawrentschuk N; Sengupta S; Hounsome L; Barber J; Jones R; Davis P; Bolton D; Persad R
BJU Int; 2014 Jan; 113(1):77-83. PubMed ID: 24053128
[TBL] [Abstract][Full Text] [Related]
11. [Advantages and risks of the use of prostate-specific antigen (PSA) in the health-care area No. 4 of Gijon (Asturias)].
Cepeda Piorno J; Rivas del Fresno M; Fuente Martín E; González García E; Muruamendiaraz Fernández V; Fernández Rodríguez E
Arch Esp Urol; 2005 Jun; 58(5):403-11. PubMed ID: 16078781
[TBL] [Abstract][Full Text] [Related]
12. Positive and negative biopsies in the pre-prostate specific antigen and prostate specific antigen eras, 1980 to 1997.
Roberts RO; Bergstralh EJ; Peterson NR; Bostwick DG; Lieber MM; Jacobsen SJ
J Urol; 2000 May; 163(5):1471-5. PubMed ID: 10751860
[TBL] [Abstract][Full Text] [Related]
13. Should prostate-specific antigen screening be offered to asymptomatic men?
van Vugt HA; Bangma CH; Roobol MJ
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1043-53. PubMed ID: 20645694
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.
Adolfsson J; Garmo H; Varenhorst E; Ahlgren G; Ahlstrand C; Andrén O; Bill-Axelson A; Bratt O; Damber JE; Hellström K; Hellström M; Holmberg E; Holmberg L; Hugosson J; Johansson JE; Petterson B; Törnblom M; Widmark A; Stattin P
Scand J Urol Nephrol; 2007; 41(6):456-77. PubMed ID: 17934985
[TBL] [Abstract][Full Text] [Related]
15. Evidence of increased prostate cancer detection in men aged 50 to 59: a review of 324,684 biopsies performed between 1995 and 2002.
Lowe FC; Gilbert SM; Kahane H
Urology; 2003 Dec; 62(6):1045-9. PubMed ID: 14665352
[TBL] [Abstract][Full Text] [Related]
16. [Diagnosis based on prostate needle biopsy: inadequate correlation between pathologic results and clinical course for individual prognosis].
van der Kwast TH; Hoedemaeker RF; Schröder FH
Ned Tijdschr Geneeskd; 2005 Apr; 149(18):972-6. PubMed ID: 15903037
[TBL] [Abstract][Full Text] [Related]
17. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.
Oesterling JE; Jacobsen SJ; Chute CG; Guess HA; Girman CJ; Panser LA; Lieber MM
JAMA; 1993 Aug; 270(7):860-4. PubMed ID: 7688054
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
Catalona WJ; Smith DS; Ornstein DK
JAMA; 1997 May; 277(18):1452-5. PubMed ID: 9145717
[TBL] [Abstract][Full Text] [Related]
20. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
